US FDA Considering Contracting IT Services To Keep Systems Up To Date, Break Down Siloes
Common system throughout FDA also could facilitate cross-center product reviews; Sentinel program is template for the approach.
You may also be interested in...
Attorneys' proposal aims to better connect dispersed rare disease expertise within FDA's drug, biologic, and device centers through more leadership, new advisory committee.
Patrizia Cavazzoni, CDER's new deputy director for operations, has safety surveillance background and wants to see FDA continue to grow its capabilities.
CDER's OHOP, as well as relevant CBER and CDRH staff, should be folded into OCE, which should have final sign-off on all oncology products, ASCO and Friends of Cancer Research say.